StockNews.com Begins Coverage on Athersys (NASDAQ:ATHX)

StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX) in a report released on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

Athersys has a 12-month low of $0.01 and a 12-month high of $1.99. The stock has a market capitalization of $833,000.00, a PE ratio of 0.00 and a beta of -0.90.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.